$MBRX
Moleculin Biotech, Inc.

2018 Q2 Form 10-Q Financial Statement

#000165961718000056 Filed on May 14, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2018 Q1 2017 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.220M $1.390M $850.0K
YoY Change 52.5% 63.53% 174.19%
% of Gross Profit
Research & Development $4.231M $1.237M $683.0K
YoY Change 721.55% 81.11% 4453.33%
% of Gross Profit
Depreciation & Amortization $7.000K $8.000K $4.000K
YoY Change 40.0% 100.0%
% of Gross Profit
Operating Expenses $5.458M $2.637M $1.535M
YoY Change 313.48% 71.79% 378.19%
Operating Profit -$5.458M -$2.637M -$1.535M
YoY Change 313.48% 71.79% 378.19%
Interest Expense $330.0K $710.0K $1.000K
YoY Change 70900.0% -90.91%
% of Operating Profit
Other Income/Expense, Net -$1.000K $0.00 $0.00
YoY Change
Pretax Income -$5.130M -$1.930M -$330.0K
YoY Change 50.0% 484.85% 0.0%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.125M -$1.927M -$329.0K
YoY Change 49.68% 485.71% -0.9%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.190M -$496.1K -$135.8K
COMMON SHARES
Basic Shares Outstanding 25.77M shares 25.77M shares 17.18M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q2 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.72M $13.11M $8.880M
YoY Change 26.43% 47.64% 3315.38%
Cash & Equivalents $11.72M $13.11M $8.881M
Short-Term Investments
Other Short-Term Assets $1.170M $630.0K $270.0K
YoY Change 44.44% 133.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $12.89M $13.75M $9.150M
YoY Change 27.88% 50.25% 3055.17%
LONG-TERM ASSETS
Property, Plant & Equipment $26.00K $33.00K $20.00K
YoY Change 30.0% 65.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $11.17M $11.18M $11.17M
YoY Change 0.05% 0.13% -3313749.85%
TOTAL ASSETS
Total Short-Term Assets $12.89M $13.75M $9.150M
Total Long-Term Assets $11.17M $11.18M $11.17M
Total Assets $24.07M $24.93M $20.32M
YoY Change 13.26% 22.7% 6914.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.676M $570.0K $860.0K
YoY Change 157.85% -33.72% 138.89%
Accrued Expenses $1.839M $766.0K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $110.0K
YoY Change -82.26%
Total Short-Term Liabilities $4.116M $1.799M $2.204M
YoY Change 124.92% -18.38% 124.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.200M $2.560M $1.970M
YoY Change 2033.33% 29.95%
Total Long-Term Liabilities $3.200M $2.560M $1.970M
YoY Change 2033.33% 29.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.116M $1.799M $2.204M
Total Long-Term Liabilities $3.200M $2.560M $1.970M
Total Liabilities $7.318M $4.359M $4.180M
YoY Change 269.6% 4.28% 327.4%
SHAREHOLDERS EQUITY
Retained Earnings -$21.50M -$16.41M
YoY Change 155.07%
Common Stock $38.27M $36.98M
YoY Change 38.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $16.75M $20.57M $16.14M
YoY Change
Total Liabilities & Shareholders Equity $24.07M $24.93M $20.32M
YoY Change 13.26% 22.68% 6915.05%

Cashflow Statement

Concept 2018 Q2 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income -$5.125M -$1.927M -$329.0K
YoY Change 49.68% 485.71% -0.9%
Depreciation, Depletion And Amortization $7.000K $8.000K $4.000K
YoY Change 40.0% 100.0%
Cash From Operating Activities -$3.460M -$2.807M -$1.391M
YoY Change 79.27% 101.8% 379.66%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $8.000K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 -$8.000K $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.060M $8.215M $5.265M
YoY Change -11.21% 56.03% 857.27%
NET CHANGE
Cash From Operating Activities -3.460M -$2.807M -$1.391M
Cash From Investing Activities 0.000 -$8.000K $0.00
Cash From Financing Activities 2.060M $8.215M $5.265M
Net Change In Cash -1.400M $5.400M $3.874M
YoY Change -458.97% 39.39% 1584.35%
FREE CASH FLOW
Cash From Operating Activities -$3.460M -$2.807M -$1.391M
Capital Expenditures $0.00 $8.000K $0.00
Free Cash Flow -$3.460M -$2.815M -$1.391M
YoY Change 79.27% 102.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q2 mbrx Shares Authorized
SharesAuthorized
80000000 shares
CY2017Q1 mbrx Stock Issued During Period Shares For Cash Initial Public Offering Net Of Stock Issuance Costs
StockIssuedDuringPeriodSharesForCashInitialPublicOfferingNetOfStockIssuanceCosts
3710000 shares
CY2018Q1 mbrx Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
15000 USD
CY2016Q2 mbrx Licensing Agreement Term
LicensingAgreementTerm
P3Y
CY2018Q1 mbrx Number Of Drug Technologies
NumberOfDrugTechnologies
3 technology
CY2018Q1 mbrx Number Of Other Drug Development Projects
NumberOfOtherDrugDevelopmentProjects
5 project
CY2018Q1 mbrx Number Of Recruitment Sites
NumberOfRecruitmentSites
1 site
CY2018Q1 mbrx Numberof Drug Candidates
NumberofDrugCandidates
6 candidate
CY2018Q1 mbrx Operating Leases Future Minimum Payments Due In Six Years
OperatingLeasesFutureMinimumPaymentsDueInSixYears
47000 USD
CY2017Q1 mbrx Proceedsfrom Issuanceof Common Stock Netof Issuance Costs
ProceedsfromIssuanceofCommonStockNetofIssuanceCosts
4460000 USD
CY2018Q1 mbrx Proceedsfrom Issuanceof Common Stock Netof Issuance Costs
ProceedsfromIssuanceofCommonStockNetofIssuanceCosts
8200000 USD
CY2018Q1 mbrx Sale Of Stock Cash And Warrant Compensation Tail Fee Period
SaleOfStockCashAndWarrantCompensationTailFeePeriod
P6M
CY2018Q1 mbrx Sale Of Stock Right Of First Refusal Period
SaleOfStockRightOfFirstRefusalPeriod
P9M
CY2018Q1 mbrx Share Based Compensation Arrangement By Share Based Payment Award Options Granted Aggregate Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedAggregateFairValue
300000 USD
CY2018Q1 mbrx Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue
1.15
CY2018Q1 dei Amendment Flag
AmendmentFlag
false
CY2018Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2018Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018Q1 dei Document Period End Date
DocumentPeriodEndDate
2018-03-31
CY2018Q1 dei Document Type
DocumentType
10-Q
CY2018Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001659617
CY2018Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25768861 shares
CY2018Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2018Q1 dei Entity Registrant Name
EntityRegistrantName
Moleculin Biotech, Inc.
CY2018Q1 dei Trading Symbol
TradingSymbol
MBRX
CY2017Q4 mbrx Accrued Clinical Testing Current
AccruedClinicalTestingCurrent
320000 USD
CY2018Q1 mbrx Accrued Clinical Testing Current
AccruedClinicalTestingCurrent
0 USD
CY2017Q4 mbrx Accrued License Fees And Sra Current
AccruedLicenseFeesAndSRACurrent
260000 USD
CY2018Q1 mbrx Accrued License Fees And Sra Current
AccruedLicenseFeesAndSRACurrent
188000 USD
CY2018Q1 mbrx Class Of Warrant Or Right Initial Exercise Period
ClassOfWarrantOrRightInitialExercisePeriod
P6M
CY2018Q1 mbrx Class Of Warrant Or Right Term
ClassOfWarrantOrRightTerm
P5Y
CY2018Q1 mbrx Employee Agreements Special Termination Benefits Numberof Employees
EmployeeAgreementsSpecialTerminationBenefitsNumberofEmployees
4 employee
CY2018Q1 mbrx Employee Agreements Termination Benefits Provided To Key Employees Aggregate Amount
EmployeeAgreementsTerminationBenefitsProvidedToKeyEmployeesAggregateAmount
1000000 USD
CY2017Q1 mbrx Gain From Settlement Liability
GainFromSettlementLiability
149000 USD
CY2018Q1 mbrx Gain From Settlement Liability
GainFromSettlementLiability
0 USD
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
810000 USD
CY2018Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
570000 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
902000 USD
CY2018Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
766000 USD
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
50000 USD
CY2018Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
75000 USD
CY2017Q4 us-gaap Accrued Salaries Current And Noncurrent
AccruedSalariesCurrentAndNoncurrent
250000 USD
CY2018Q1 us-gaap Accrued Salaries Current And Noncurrent
AccruedSalariesCurrentAndNoncurrent
437000 USD
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
21000 USD
CY2017Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
190000 USD
CY2018Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
32000 USD
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21469109 shares
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25768861 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21469109 shares
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25768861 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
21000 USD
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
26000 USD
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
31577000 USD
CY2018Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
36951000 USD
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
242000 USD
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
809000 USD
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
110000 USD
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
242000 USD
CY2017Q4 us-gaap Assets
Assets
19483000 USD
CY2018Q1 us-gaap Assets
Assets
24929000 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
8302000 USD
CY2018Q1 us-gaap Assets Current
AssetsCurrent
13748000 USD
CY2016Q2 us-gaap Business Combination Consideration Transferred Equity Interests Issued And Issuable
BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
750000.00 USD
CY2016Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
1000000.0 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5007000 USD
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8881000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7714000 USD
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13114000 USD
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3874000 USD
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5400000 USD
CY2018Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.80
CY2018Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.80
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2018Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0 USD
CY2017Q1 us-gaap Deferred Compensation Arrangement With Individual Compensation Expense
DeferredCompensationArrangementWithIndividualCompensationExpense
38000 USD
CY2018Q1 us-gaap Deferred Compensation Arrangement With Individual Compensation Expense
DeferredCompensationArrangementWithIndividualCompensationExpense
0 USD
CY2017Q4 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
150000 USD
CY2018Q1 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
150000 USD
CY2017Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4000 USD
CY2018Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8000 USD
CY2017Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
503000 USD
CY2018Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
463000 USD
CY2017Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0 USD
CY2018Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2410000 USD
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2017Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
CY2018Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
1600000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8215000 USD
CY2017Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8000 USD
CY2018Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
5000 USD
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
287000 USD
CY2018Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
CY2018Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y0M12D
CY2018Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2500000 USD
CY2017Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1059000 USD
CY2018Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-709000 USD
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
848000 USD
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1392000 USD
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-239000 USD
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-238000 USD
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-136000 USD
CY2017Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
55000 USD
CY2018Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
46000 USD
CY2017Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
11148000 USD
CY2018Q1 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
11148000 USD
CY2017Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1000 USD
CY2018Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1000 USD
CY2017Q1 us-gaap Interest Paid
InterestPaid
0 USD
CY2018Q1 us-gaap Interest Paid
InterestPaid
1000 USD
CY2017Q4 us-gaap Liabilities
Liabilities
2365000 USD
CY2018Q1 us-gaap Liabilities
Liabilities
4359000 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19483000 USD
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24929000 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2215000 USD
CY2018Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1799000 USD
CY2018Q1 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
2873000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5265000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1391000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2807000 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-329000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-1927000 USD
CY2018Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
1535000 USD
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
2637000 USD
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1535000 USD
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2637000 USD
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
296000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-14480000 USD
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16400000 USD
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16407000 USD
CY2018Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
8200000 USD
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1237000 USD
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
56000 USD
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
54000 USD
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
53000 USD
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
52000 USD
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
0 USD
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
34000 USD
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
22000 USD
CY2018Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
66000 USD
CY2017Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
1000 USD
CY2018Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
0 USD
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8000 USD
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
588000 USD
CY2018Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
634000 USD
CY2017Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
1240000 USD
CY2018Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
9000000 USD
CY2017Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
805000 USD
CY2018Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
15000 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33000 USD
CY2018Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33000 USD
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
683000 USD
CY2017Q1 us-gaap Sales Revenue Net
SalesRevenueNet
0 USD
CY2018Q1 us-gaap Sales Revenue Net
SalesRevenueNet
0 USD
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
110000 USD
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
242000 USD
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
85000 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.20
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
80000 USD
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
230000 shares
CY2017Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
89000 USD
CY2018Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
0 USD
CY2018Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5122000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
17118000 USD
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.32
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
83000 USD
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
80000 USD
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1345000 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1575000 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.50
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.25
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.76
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P2Y5M
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.93
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.81
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y26D
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M7D
CY2018Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
20570000 USD
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14590220 shares
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23331685 shares
CY2018Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Reclassifications &#8211;</font><font style="font-family:inherit;font-size:10pt;"> A reclassification was made to the prior period financial statements to conform to the </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> presentation. Such reclassification did not affect net loss as previously reported. Historically, "accrued expenses and current liabilities" were included in the line item "accounts payable and accrued expenses".</font></div></div>
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates in Financial Statement Presentation -</font><font style="font-family:inherit;font-size:10pt;"> The preparation of these financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name View Source Status
0001659617-18-000056-index-headers.html Edgar Link pending
0001659617-18-000056-index.html Edgar Link pending
0001659617-18-000056.txt Edgar Link pending
0001659617-18-000056-xbrl.zip Edgar Link pending
a2018q110q.htm Edgar Link pending
a2018q1ex311.htm Edgar Link pending
a2018q1ex312.htm Edgar Link pending
a2018q1ex321.htm Edgar Link pending
a2018q1ex322.htm Edgar Link pending
exh101leaseagreement5300me.htm Edgar Link pending
exh102licensemda18-010fina.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
leaseagreementmemoria_image1.jpg Edgar Link pending
leaseagreementmemoria_image2.jpg Edgar Link pending
mbrx-20180331.xml Edgar Link completed
mbrx-20180331.xsd Edgar Link pending
mbrx-20180331_cal.xml Edgar Link unprocessable
mbrx-20180331_def.xml Edgar Link unprocessable
mbrx-20180331_lab.xml Edgar Link unprocessable
mbrx-20180331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v471975_img02.jpg Edgar Link pending